Loading…
NuCana plc is projected to decline to $1.22 by 2027, a -2% move from its current price of $1.24. NCNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.19 | $1.24 | $1.29 | -0.01% |
| Jul 13 | $1.17 | $1.24 | $1.31 | -0.02% |
| Jul 14 | $1.15 | $1.24 | $1.33 | -0.03% |
| Jul 15 | $1.14 | $1.24 | $1.35 | -0.04% |
| Jul 16 | $1.13 | $1.24 | $1.36 | -0.04% |
| Jul 17 | $1.12 | $1.24 | $1.37 | -0.05% |
| Jul 18 | $1.11 | $1.24 | $1.38 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.11 | $1.24 | $1.38 | -0.06% |
| Week 2 | $1.06 | $1.24 | $1.44 | -0.12% |
| Week 3 | $1.03 | $1.24 | $1.49 | -0.19% |
| Week 4 | $0.9958 | $1.24 | $1.54 | -0.25% |
| Week 5 | $0.97 | $1.24 | $1.58 | -0.31% |
| Week 6 | $0.9473 | $1.24 | $1.61 | -0.37% |
| Week 7 | $0.9268 | $1.23 | $1.64 | -0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NuCana plc is a clinical-stage biopharmaceutical company focused on developing medicines to treat cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors.
NuCana has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
NuCana plc, NCNA, is currently trading at $1.24 per share with a market capitalization of $5.16M and a market rank of 5318.
The near-term price picture is neutral, with the 2026 forecast showing a min of $1.24, an average of $1.24, a max of $1.49 and a 0% ROI; the 2027 forecast shows a min of $0.923, an average of $1.22, a max of $1.72 and a -1.9% ROI.
Over the longer horizon, the forecast turns bullish, with 2029 avg $1.68 and ROI 35.5; 2030 avg $1.58 ROI 27.5; 2031 avg $1.51 ROI 21.4; 2032 avg $1.61 ROI 29.7. Further years show continued growth: 2035 avg $1.99 ROI 60.3; 2040 avg $2.14 ROI 72.2; 2050 avg $4.20 ROI 239.1.
A major floor 55.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 87.9% above — a clean break opens room to run.
A major ceiling 119.9% above — clearing it would confirm fresh momentum.
Key NCNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NCNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.34 | Sell | $1.34 | Sell |
| MA 10 | $1.41 | Sell | $1.42 | Sell |
| MA 20 | $1.62 | Sell | $1.57 | Sell |
| MA 50 | $1.89 | Sell | $1.80 | Sell |
| MA 100 | $1.92 | Sell | $2.72 | Sell |
| MA 200 | $2.85 | Sell | $26.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.20 | Neutral |
| Stoch RSI (14) | 46.92 | Neutral |
| CCI (20) | -89.70 | Neutral |
| Williams %R (14) | -83.05 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -22.54 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 16.95 | Buy |
| TRIX (15) | -1.18 | Sell |
| Awesome (5,34) | -0.47 | Sell |
| Ultimate (7,14,28) | 25.30 | Buy |
| Momentum (10) | -0.26 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.27 | Sell |
| ADX (14) | 29.44 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL. RSI(14) is 20, indicating limited near-term momentum. The 50-day simple moving average is $1.91 and the 200-day simple moving average is $2.86, with price currently at $1.24.
There is support at $1.24 and resistance at $2.33. The 30-day price range spans from a low of $0.9466 to a high of $1.62.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.24 | $1.24 | $1.49 | 0% | Neutral | |
| $0.9225 | $1.22 | $1.72 | -2% | Neutral | |
| $1.05 | $1.45 | $2.16 | +17% | Neutral | |
| $1.18 | $1.68 | $2.61 | +36% | Bullish | |
| $1.07 | $1.58 | $2.53 | +28% | Bullish | |
| $0.9859 | $1.50 | $2.48 | +21% | Bullish | |
| $1.03 | $1.61 | $2.73 | +30% | Bullish | |
| $0.865 | $1.39 | $2.41 | +12% | Neutral | |
| $0.896 | $1.48 | $2.62 | +20% | Neutral | |
| $1.17 | $1.99 | $3.58 | +60% | Bullish | |
| $1.11 | $2.13 | $4.17 | +72% | Bullish | |
| $1.90 | $4.21 | $9.24 | +240% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.24 | $1.24 | $1.54 | +0.00% |
| August 2026 | $1.09 | $1.31 | $1.62 | +5.39% |
| September 2026 | $1.02 | $1.23 | $1.55 | -5.88% |
| October 2026 | $0.9485 | $1.16 | $1.48 | -5.88% |
| November 2026 | $0.9518 | $1.17 | $1.51 | +1.14% |
| December 2026 | $0.9229 | $1.14 | $1.49 | -2.34% |
Click any year to see its month-by-month NCNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NCNA could reach as high as $1.49, with a base case around $1.24 and support toward $1.24 — roughly 0% from $1.24. A consolidation phase looks the most probable path here.
Expect NCNA to range from $0.9225 to $1.72 through 2027. The $1.22 average target implies a -2% move from current prices. That is -2% versus the projected 2026 average. Price action looks broadly range-bound.
The NCNA price prediction for 2028 points to an average of $1.45 (low $1.05, high $2.16) — a potential gain of +17% on today's $1.24. A consolidation phase looks the most probable path here.
In 2029, NCNA is projected to trade between $1.18 and $2.61, averaging $1.68 — a potential gain of +36% from today's $1.24. That is up +16% on the projected 2028 average. Momentum favours further upside here.
NuCana plc's 2030 outlook centres on $1.58, within a $1.07 to $2.53 range. That is -6% versus the projected 2029 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, NCNA could reach as high as $2.48, with a base case around $1.50 and support toward $0.9859 — roughly +21% from $1.24. Momentum favours further upside here.
Expect NCNA to range from $1.03 to $2.73 through 2032. The $1.61 average target implies a +30% move from current prices. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The NCNA price prediction for 2033 points to an average of $1.39 (low $0.865, high $2.41) — a potential gain of +12% on today's $1.24. Price action looks broadly range-bound.
In 2034, NCNA is projected to trade between $0.896 and $2.62, averaging $1.48 — a potential gain of +20% from today's $1.24. That is up +6% on the projected 2033 average. A consolidation phase looks the most probable path here.
NuCana plc's 2035 outlook centres on $1.99, within a $1.17 to $3.58 range. That is up +34% on the projected 2034 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2040, NCNA could reach as high as $4.17, with a base case around $2.13 and support toward $1.11 — roughly +72% from $1.24. Buyers look set to stay in control over this stretch.
Expect NCNA to range from $1.90 to $9.24 through 2050. The $4.21 average target implies a +240% move from current prices. That is up +98% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NCNA today (≈ 806.451613 NCNA) could be worth
$3,396.9
+$2,396.9 (+240%) by 2050 · US Dollar
Based on the average projected NCNA price of $4.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NCNAwould be worth at today's price.
$1,000 invested in NCNA on Jul 10, 2025 (≈ 83.333333 NCNA) would be worth
$103.33
-$896.67 (-89.7%) today · 0.10× · US Dollar
Based on a NCNA entry price of $12 vs. today's $1.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.36 | $911.76 | -8.8% |
| 1 month ago | $1.95 | $635.9 | -36.4% |
| 3 months ago | $1.97 | $629.44 | -37.1% |
| 6 months ago | $3.3 | $375.76 | -62.4% |
| 1 year ago | $12 | $103.33 | -89.7% |
| All time (5.0y) ago | $13,000 | $0.1 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NCNA forecast.
Our base-case forecast reaches $2.50 around 2050.
Implied market cap at $2.50: $10.4M
In the near term, the forecast shows a neutral stance for 2026 and 2027, with 2026 averaging $1.24 and 2027 averaging $1.22; the 2027 high reaches $1.72 while the 2027 ROI is -1.9%. This sets a backdrop of limited upside in the very near term.
From 2028 through 2032, the outlook improves, with 2028 averaging $1.45 and 2029 averaging $1.68 with ROI 35.5; 2030 averaging $1.58 with ROI 27.5; 2031 averaging $1.51 with ROI 21.4; 2032 averaging $1.61 with ROI 29.7.
The forecast cools slightly for 2033 and 2034 (neutral), then turns strongly bullish by 2035 with average $1.99 and ROI 60.3, followed by 2040 average $2.14 and ROI 72.2, and a peak in 2050 with average $4.20 and ROI 239.1. These figures illustrate a path where longer horizons exhibit meaningful upside despite mid-term variability.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.58, with a minimum of $1.07 and a maximum of $2.53. The ROI is 27.5% and the sentiment is BULLISH.
Near-term forecasts are NEUTRAL (2026 min $1.24, avg $1.24, max $1.49, ROI 0). Longer-term forecasts turn BULLISH, with higher ROIs in years like 2029 (ROI 35.5) and 2050 (ROI 239.1). These are estimates, not guarantees.
The forecast maximum in 2050 is $9.22, with an average of $4.20 and a bullish sentiment. This suggests a path where the price could exceed $5 at some point in the forecast horizon, reaching as high as $9.22 in 2050.
The current price is $1.24 per share and the market capitalization is $5.16M. The market rank is 5318.
The 30-day technical picture is NEUTRAL. RSI(14) is 20; SMA50 is $1.91; SMA200 is $2.86. There is support at $1.24 and resistance at $2.33. The 30-day range is $0.9466 to $1.62.
NuCana plc Community Discussion
0Share your NuCana plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.